Aquestive Therapeutics stock
AQSTNASDAQAquestive Therapeutics, Inc., HealthcareISIN US03843E1047
29Score 29 out of 100, Weak
Price and trend
43 / 100
Price history
−36% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 15% below it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 33).
The price is 46% below its 52-week high. Largest decline in 8 years: 97% (September 2018 to July 2022).
Chart figures for advanced users
- SMA 50$4.40
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.22
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)33
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.95
- The lowest closing price of the last twelve months.
- Resistance$6.62
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Aquestive Therapeutics, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $448.71M, is number 74 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $44.55M (down 22.6% year on year) and a loss of $83.78M.
- For fiscal 2026, analysts expect on average revenue of $49.5M (up 11.1%) and adjusted earnings per share of −$0.47.
Show more
- MEQIRI Score 29 out of 100 (Weak): rank 695 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 262% since 2020.Capital allocation 18
- Loss-makingLoss of $79.28M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$40.7M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 12.5% on the twelve months before. Revenue has stayed largely stable since 2016.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 61%, operating −156%, net −188%. Last 12 months: net −100%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 3 Nov 2026EPS reported −$0.13 (expected −$0.12)below expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 4.5% since 15 Oct 2026.
- Earnings per share
- −$0.47+4.5%
- Revenue
- $49.5M−0.9%
- Earnings per share
- −$0.49+2.4%
- Revenue
- $67.91M+0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −3.6%Expectation unchanged: $75 million launch funding from RTW and $20 million from Oaktree after FDA approval of Anaphylm.
“Combined with the flexibility provided by our Oaktree facility and the expected availability of $75 million in launch funding from RTW and $20 million from Oaktree following FDA approval of Anaphylm, we believe we are well positioned to support our planned commercial strategy and launch preparation.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $99,331 in total. 3 insiders sold, $743,938 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Daly Richard JPurchase
10 Nov 2026, Board
- Shares
- 28,025
- Price
- $3.54
- Value
- $99,331
- Barber DanielSale
15 Oct 2026, President and CEO
- Shares
- 25,000
- Price
- $4.22
- Value
- $105,600
- Barber DanielSale
15 Sept 2026, President and CEO
- Shares
- 25,000
- Price
- $4.82
- Value
- $120,487
Show 7 more
- Korczynski SherrySale
9 Sept 2026, Chief Commercial Officer
- Shares
- 8,750
- Price
- $5.22
- Value
- $45,675
- Barber DanielSale
17 Aug 2026, President and CEO
- Shares
- 25,000
- Price
- $4.29
- Value
- $107,168
- Barber DanielSale
16 Jul 2026, President and CEO
- Shares
- 20,369
- Price
- $4.00
- Value
- $81,509
- Barber DanielSale
15 Jul 2026, President and CEO
- Shares
- 4,631
- Price
- $4.03
- Value
- $18,683
- Krop JulieSale
23 Jun 2026, Board
- Shares
- 25,000
- Price
- $5.02
- Value
- $125,393
- Barber DanielSale
15 Jun 2026, President and CEO
- Shares
- 25,000
- Price
- $4.16
- Value
- $104,010
- Barber DanielSale
15 May 2026, President and CEO
- Shares
- 8,257
- Price
- $4.29
- Value
- $35,413
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Aquestive Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 29
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- EvotecEVT.DE $624.43M32
- Alpha TeknovaTKNO $541M43
- EvolusEOLS $491.12M45
- KamadaKMDA $468.95M66
- BoironBOI.PA $371.89M56
- PharmaSGP HoldingPSG.DE $371.49M80
- Aurora CannabisACB $332.01M44
- Emergent BioSolutionsEBS $310.55M24
ETFs that hold Aquestive Therapeutics
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.